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surgical procedures, but also the administration of medicines to control lipids, 
blood pressure, antidepressants and even hypoglycemia, and even then those 
expenditures does not consider the indirect expenses such as transportation and 
escort the patient to the hospital and absence from work.  
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OBJECTIVES: To determine the components and the costs of an exercised-based 
rehabilitation program for patients with chronic systolic HF, from the point of 
view of the provider of the service. METHODS: Systematic review of the 
literature and expert consensus. Identification of components of HF 
rehabilitation programs, based on the literature, and Delphi rounds of experts for 
consensus. Only variable costs associated with the components of the program 
were estimated, based on the Colombian 256 agreement of 2001 (the Colombian 
norm that set the tariff for reimbursement for health care services) plus 23%, 
30%, or 48%, to approximate the range of costs in current (2012) health care 
package negotiations in Colombia between providers and payers. For 2012, 
US$1=COL$1,783. RESULTS: Based on expert consensus of cardiologists and 
physical therapists, 18 components of the rehabilitation program were identified. 
After the second round, over 80% agreement was obtained for the remaining 
three components, and an additional component was identified. After the third 
round, consensus was obtained for a program of 36 rehabilitation sessions and 
19 components. With the base-case scenario of agreement 256 plus 30%, the cost 
per session of the program was inversely proportional to the number of patients 
in each session: COL $96,903 for one patient, and COL $11,623 for 15 patients. For 
a program with 10 patients per session, the costs of a program may range from 
COL$ 471,130 to COL $656,554, depending on the agreement type. CONCLUSIONS: 
Agreement is critical to unify criteria on the components of a rehabilitation 
program that is both effective and safe for patients with HF. From the point of 
view of the provider, variable costs associated with implementation are sensitive 
to the number of patients per session. This study should set the basis for the 
estimation of the cost-effectiveness of rehabilitation programs in heart failure.  
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OBJECTIVES: Although the Advisory Committee for Immunization Practices 
(ACIP) and other organizations recommend annual influenza vaccination for 
cardiovascular disease patients (CVD), the vaccination rate is low in this risk 
group. Economic assessment of vaccination will aid public officials plan 
campaigns to increase coverage. METHODS: We estimated using a Monte Carlo 
(probabilistic) spreadsheet-based decision tree, the cost-effectiveness of 
vaccination to prevent hospitalization and death in all 27.1 million CVD patients 
in the US. We then estimated the benefit-cost ratios (BCR) associated with 
hospitalization and death averted by increasing coverage rates by 10% in all 
adult CVD patients from the current rates of 45% and 65% (for ages <65 years and 
≥65 years, respectively). Finally, we estimated the BCR associated with reaching 
the healthy people 2020 goal of vaccinating 90% of person’s ≥65 years and 80% of 
adults’ <65 years. We obtained treatment cost data from Marketscan database 
(2005-2010) and epidemiological data from the literature. We performed the 
analysis from the health care perspective including only cost associated with 
hospitalization and vaccination and reporting median cost values. RESULTS: 
Vaccination of all 27.1 million CVD patients’ would result in the following: 20,738 
(S.D 48,387)) quality-adjusted life years (QALY) saved, $10,107 (95% CI: cost-
savings (CS) to $70,554) / QALY saved, $31,563 (CI: CS to $151,900)/ hospitalization 
averted, and $76,588 (CI: CS to $534,658)/ premature death averted. The base case 
BCR is 0.52. A 10% increase in vaccination rate costing $41.2million (S.D $7.2 
million) would result in hospitalization-related savings of $28 million (S.D. $165 
million) (BCR=0.68). Achieving healthy 2020 goal would cost $257 million (S.D. $45 
million) and result in $ 216 million (S.D. $1.4 billion) hospitalization savings 
(BCR=0.84). CONCLUSIONS: Increasing vaccination coverage rate among CVD 
patients will avert hospitalization and most likely deaths, but with variability in 
economic impact.  
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OBJECTIVES: Erectile dysfunction is a common male sexual disorder worldwide. 
Three oral medications – sildenafil, vardenafil, and tadalafil – have been used to 
treat erectile dysfunction. This study aimed to conjointly evaluate the 
therapeutic risks and benefits of the three medications to assist decision making 
of prescribing from the perspective of both physicians and patients. METHODS: 
A decision model was created to compare the risk-benefit of the aforementioned 
medications. Using published meta-analysis data, we performed a probabilistic 
Monte Carlo simulation to estimate the joint distribution of each type of adverse 
event (i.e., risk; categories included: any adverse event, serious cardiovascular 
(CV) events, headache, flushing, and dyspepsia) and effectiveness (defined as 
proportion of patients with improved erections). The incremental risk-benefit 
ratios (ICBRs) were calculated, and the results were illustrated by incremental 
risk–benefit planes. To account for differential risk preferences across patients, 
the results were also illustrated using risk–benefit acceptability curves and net-
benefit curves. RESULTS: When risk was defined as having any adverse event, 
serious CV event, or headache, sildenafil was dominated by vardenafil (ICBR= 
-1.00, -0.20, and -3.20, respectively); tadalafil showed increasing risk and benefit 
as compared to vardenafil (ICBR=0.83, 0.03, and 0.13, respectively). Tadalafil 
dominated sildenafil and vardenafil when balancing between the risk of 
flushing/dyspepsia and the drug efficacy. CONCLUSIONS: Based on patients’ 
concern of various categories of adverse events and assuming negligible concern 
over medical costs, vardenafil or tadalafil may be preferred over sildenafil.  
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OBJECTIVES: In 2011, investments in continuing medical education (CME) 
exceeded $2 billion. Few studies report the economic impact of CME activities. 
Greater understanding of the economic value of CME assists stakeholders and 
health care cost payers in resource allocation. It is not feasible to obtain patient-
level data after each CME activity. We developed a model to estimate the 
potential health care cost savings associated with CME activity outcomes. 
METHODS: We evaluated data from a certified CME symposium for surgeons 
that reviewed the Society for Thoracic Surgeons (STS) blood conservation 
guidelines. The activity promoted prevention of bleeding-related complications 
(BRCs). We estimated the potential savings of averted BRCs from the provider 
perspective predicted by participants' self-reported commitment to change 
(CTC). Model parameter estimates were from: 1) costs of BRCs in 103,826 cardiac 
operations; 2) costs of reoperation for bleeding in 133,001 coronary artery bypass 
graft surgeries; 3) operative volume from the STS workforce report. The base case 
was 3 in 10 participants preventing one BRC in 2% of operations over 1 year. 
Probabilistic sensitivity analysis (PSA) using second-order Monte Carlo 
simulations was used to model parameter uncertainty. Results were 
standardized to 2012 $US using the medical care component of the Consumer 
Price Index. RESULTS: 93.8% of participants (n=133) reported CTC, a validated 
measure of behavior change. For BRCs, the savings for the base case was 
$1,500,112. PSA estimated the mean savings as $1,502,769 (95% CI, $869,860–
$2,359,068). For reoperation for bleeding, the savings for the base case was 
$2,974,497. PSA estimated the mean savings as $2,959,117 (95% CI, $1,135,992–
$5,566,487). CONCLUSIONS: Plausible economic estimates suggest that CME-
related learning favorably impacting clinical practice yields substantial cost 
savings. Model prediction of averted costs associated with CME allows 
estimation of the economic impact on surgical outcomes in the absence of 
patient-level outcomes data related to CME activities.  
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OBJECTIVES: Advanced heart failure (HF) is a leading cause of death in developed 
countries with a one-year mortality rate estimated at 40% after the first 
hospitalization. In France, HF affects 150 000 persons with annual costs of up to 
1,6 billon euros. Cardiac transplantation is the most effective treatment. 
However, because of a limited donor organ supply, innovative technics as left 
ventricular assist devices (LVAD) are developed as bridge to transplantation for 
over 10 years. The aim of this study is to assess the medical and economic 
consequences of LVAD in adults with advanced HF in France. METHODS: 
Between April 2008 and November 2011, 55 patients were included in this study 
in 14 French hospitals and were followed during one year after implantation. The 
primary medical outcome was the discharge at home and secondary medical 
outcome was the final situation of patient. This prospective economic analysis 
adopted the health care payer’s perspective and took into account direct medical 
and non-medical costs. RESULTS: This intermediate analysis included 21 
patients. LVAD used are HeartMate II (n=12), Jarvik 2000 (n=8) and Ventrassist 
(n=1). On the 21 patients, 15 were discharged at home spending an average of 265 
days (8.7 months) at home. During the follow-up period, 4 patients were 
transplanted, 6 patients died, and 11 were still on device at home. The mean 
total cost per implanted patient was €161,843 (±36,533). The device and initial 
hospitalization are the most important costs and represent respectively 58% and 
30% of the total cost. One day spent at home costs in average €59 CONCLUSIONS: 
Continuous-flows LVAD represent a costly strategy in the HF treatment. 
However, LVAD allow the patient to be discharged at home instead of awaiting 
heart transplantation at hospital.  
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OBJECTIVES: Improved peri- and postoperative clinical outcomes can result in 
economic savings for hospitals and payers. While the relative effectiveness of 
topical hemostatic agents in the termination of bleeding during cardiac 
operations has been demonstrated, the economic benefit has not been 
evaluated. An economic analysis quantified the reduction in costs associated 
with efficient control of intraoperative bleeding. METHODS: Based on a cost-
consequence framework, an economic model computed incremental annual 
outcomes and cost savings from use of a Hemostatic Matrix (FLOSEAL) versus 
other topical hemostatic agents. The model captured cost implications of 
acquisition, operating room time, complications, blood transfusions and surgical 
revisions due to bleeding associated with cardiac surgery procedures. Clinical 
outcomes data were from a prospective controlled study evaluating whether the 
use of a Hemostatic Matrix correlates to a decrease in postoperative bleeding-
related events and complications relative to a control group using other 
hemostatic agents in a cohort of mixed-cardiothoracic aortic procedures (Nasso 
et al., 2009). Base-case costs, expressed in 2012 USD, were obtained through US 
cost database analyses and literature. Surgery and care related costs were 
regionally adjusted by economically influenced wage indices. Cost savings were 
determined based on a hypothetical annual number of cases. RESULTS: Effective 
hemostasis with a Hemostatic Matrix, when compared with a control group, 
results in cost savings through reduced OR time, reduced need for surgical 
revision, fewer blood transfusions and fewer post-operative complications. For a 
facility that conducts 600 cardiac surgeries annually, the net annualized cost 
savings is $5.2 million with the reduction in complications contributing the 
largest portion of the savings. CONCLUSIONS: The present economic model is 
reliable in evaluating hospital cost fluctuations associated with the use of 
hemostatic agents in cardiac surgery. These analyses strongly indicate 
significant savings if the Hemostatic Matrix is routinely employed in a cohort of 
mixed cardiothoracic aortic surgical procedures.  
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OBJECTIVES: Transcatheter radiofrequency ablation (RFA) is one of the primary 
treatments for symptomatic drug-refractory atrial fibrillation (AF) and it is 
considered the first-line therapy for other arrhythmias. One of the major 
complications of procedure is cardiac perforation and tamponade, which can 
occur in cardiac chambers. Contact force technology is an important predictor of 
RFA efficacy and safety, a cost-consequence analysis between standard ablation 
catheter and Thermocool®SmartTouch™ catheter for RFA of AF has been 
developed in order to evaluate the introduction of the contact force in clinical 
practice of Terni’s hospital. METHODS: An excel model was developed to 
simulate a cost-consequence analysis based on literature review and 
economic/organizative data collection. The means, standard deviation and 95% 
confidence intervals for the analysis were estimated using Bayesian methods 
(10,000 simulations) and assuming a reduction in terms of procedure time, 
complications and recurrence with the use of Thermocool®SmartTouch™ 
catheter. The analysis estimated the cost per procedure and per patient from 
hospital perspective in 1 year time horizon. RESULTS: The average total cost 
(including consumables, room, personnel and complications costs) was 
estimated at 9,201€ (95%IC 7,629-11,251€) for Thermocool® SmartTouch™ 
procedure and 9,460€ (95%IC 7,885-11,577€) for standard procedure. The 
consequences were estimated as procedure cost per patient, assuming the re-
treatment reduction with Thermocool® SmartTouch™. The procedure cost per 
patient was estimated at 11,501€ (95%IC 9,234-14,602€) with Thermocool® 
SmartTouch™ and at 13,515€ (95%IC 10,883-17,324€) with standard. Moreover, 
both procedure and fluoroscopy time have been calculated respectively: 199 and 
40 minutes for Thermocool®SmartTouch™ catheter vs 284 and 57 minutes for 
standard catheter. CONCLUSIONS: Thermocool® SmartTouch™ technology 
appears cost-savings and the consequences management results to be favorable. 
The results were consistent according to the developed probabilistic sensitivity 
analysis, but they could be different in real clinical practice, therefore it is 
necessary to collect data after Thermocool® SmartTouch™ introduction for 
validating the results simulated.  
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OBJECTIVES: To determine the cost-effectiveness of using a platelet reactivity 
assay (PRA) to aid in the selection between dual antiplatelet treatment strategies 
for acute coronary syndrome (ACS) patients. METHODS: A hybrid decision 
tree/Markov model was used to calculate 5-year costs (2011 US$), quality-
adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) of 
1-year of universal clopidogrel, ticagrelor or prasugrel (given to all patients) or 
PRA-driven ticagrelor or prasugrel (given to patients with high platelet reactivity 
defined as >230 on the VerifyNow P2Y12 assay, others got generic clopidogrel). 
We assumed a cohort of 65-year-old ACS patients and 32% and 13% incidences of 
high platelet reactivity ~24-48 hours post-revascularization and at 1-month. The 
analysis was conducted from a US payer perspective and used a 1-year cycle 
length. Data depicting the efficacy and safety of dual antiplatelet treatment were 
taken from randomized trials. RESULTS: The PRA-driven ticagrelor and prasugrel 
strategies were cost-effective compared to universal clopidogrel (ICERs=$40,100 
and $49,143/QALY); however, universal ticagrelor and prasugrel strategies were 
not (ICERs=$61,651 and $96,261/QALY). Monte Carlo simulation suggested PRA-
driven ticagrelor, PRA-driven prasugrel, universal ticagrelor and universal 
prasugrel would have ICERs<$50,000/QALY (be cost-effective) in 52%, 40%, 23%, 
and 2% of 10,000 iterations versus universal clopidogrel. Universal ticagrelor or 
prasugrel were also not found to be cost-effective strategies compared to the 
PRA-driven use of these same agents (ICERs=$68,182 and $116,875/QALY, 
respectively). Monte Carlo simulation suggested universal selection of ticagrelor 
and prasugrel would have ICERs<$50,000/QALY in only 26% and 4% of 10,000 
iterations compared to their PRA-driven use. The model’s conclusions were most 
sensitive to differences in antiplatelet agent costs and drug-specific relative risks 
of death. CONCLUSIONS: Even in the age of generic clopidogrel, PRA-driven 
selection of antiplatelet therapy appears to be a cost-effective strategy with the 
potential to decrease overall ACS associated health care costs.  
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OBJECTIVES: Ticagrelor has been shown to reduce acute coronary syndrome 
(ACS)-related complications, but with a higher incidence of bleeding and greater 
acquisition cost than generic clopidogrel. This study was designed to assess the 
cost-effectiveness of ticagrelor use compared with clopidogrel in ACS patients 
from the US health system perspective. METHODS: A decision model was 
developed and the probabilities of complications including myocardial infarction 
(MI), ischemic stroke (IS), vascular death, and major bleeding events were 
defined based on the Platelet Inhibition and Patient Outcomes (PLATO) trial and 
sub studies. Cost inputs were identified from a systematic literature review and 
from Healthcare Cost and Utilization Project (HCUP) databases. Life expectancy 
for PLATO population was estimated using DEALE method. All costs were 
adjusted to 2012 US dollars. Utility estimates for complications were identified 
from peer reviewed studies, and quality-adjusted life years (QALYs) were 
projected to measure effectiveness. Lifetime costs and cost-effectiveness were 
calculated. One-way sensitivity analyses were performed on all variables. 
RESULTS: In the base case analysis, ticagrelor treatment ($58,922.91 and 10.2579 
QALYs) provided 0.1243 more QALYs but cost $23,566.60 more than clopidogrel 
($35,366.30 and 10.1336 QALYs). The incremental cost-effectiveness ratio (ICER) 
for the ticagrelor treatment was $189,468.79/QALY. Results were sensitive to the 
cost (50% to 200% range) of ticagrelor ($57,167.95 to $454,066.84 per QALY), the 
cost of clopidogrel ($228,166.51 to $112,069.80 per QALY), and the hazard ratio 
(95% confidence interval range) of vascular death ($135,710.24 to $358,837.65 per 
QALY). The ICER was less than $100,000/QALY only if the daily acquisition cost of 
ticagrelor was lower than $4.88 (i.e., about 66% of the daily cost in the base case). 
CONCLUSIONS: At its current price, ticagrelor was not a cost-effective treatment 
strategy in patients with ACS compared to generic clopidogrel, using either 
$50,000 or $100,000/QALY as the ICER threshold.  
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OBJECTIVES: Type-2 diabetes in France has increased in prevalence over the past 
decade and there is a need to examine cardiovascular outcomes based on real-
world evidence (RWE). The CANARD model was developed to evaluate the cost-
effectiveness (CE) of treatments using data from a RWE French population in the 
IMS LifeLinkTM Diabetes Cohort database. METHODS: A Markov micro-simulation 
model was developed in Microsoft Excel 2007® using the United Kingdom 
Prospective Diabetes Study (UKPDS) risk equations to predict cardiovascular 
outcomes (MI, stroke, death). Four treatment pathways taken from the IMS 
LifeLinkTM Diabetes Cohort database were evaluated, which included step-wise 
treatment switches based on the patient’s HbA1c. Treatments within the 
pathway included diet and exercise, metformin (MF), oral anti-diabetics (OADs) 
of sulfonylurea (SU) or dipeptidyl peptidase IV (DDP-IV) in addition to MF, a lipid 
lowering agent (atorvastatin) in addition to MF and an OAD, and insulin. CE 
outcomes in 13 subgroups were explored and uncertainty in the model was 
evaluated with a probabilistic sensitivity analysis (PSA) and expected value of 
perfect information (EVPI). The model was validated by comparing the predicted 
results to the database results at 18 months. RESULTS: The results showed that 
the treatment pathway including SU with atorvastatin was the most cost-
effective in the general population at €2,640/QALY. The results from the PSA 
showed that the likelihood of this treatment pathway being cost-effective was 
0.61 at willingness-to-pay (WTP) of €20,000/QALY, and 0.56 at a WTP of 
€50,000/QALY. EVPI at a WTP of €20,000/QALY and €50,000/QALY were €476 per 
patient and €1,427 per patient respectively. The subgroup results demonstrated 
that depending on the WTP of the French National Health Service, several 
treatments pathways may be CE. CONCLUSIONS: Overall, SU with atorvastatin 
was the most cost-effective treatment for a French type II diabetic population, 
however, uncertainty was evident and therefore, future research would be of 
value.  
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